April 11, 2017
Takeda Pharmaceutical said on April 10 that it will sell seven additional long-listed products, or off-patent brand-name drugs, in Japan to Teva Takeda Yakuhin for 28.5 billion yen, effective May 1. Subject to the sale are type 2 diabetes drugs...read more